Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past decade, an armamentarium of biologic and targeted therapies has led to better control of disease activity in patients with rheumatoid arthritis. Whether these patients, especially those receiving newer biological and targeted therapies such as JAK inhibitors, are at an increased risk of severe COVID-19 outcomes remains uncertain.
All News
Article
Marie Kuchynski MD
Tweet
plenary I. #ACR21
Interesting data with the delta variant from @alhkim https://t.co/oUCOXSc9wA
Richard Conway
Tweet
@alhkim presenting COVaRiPAD data on SARS-CoV-2 vaccination. Most mount immune response. Risk of poor response BCDT >> MMF >> GCC > MTX/AZA/JAKi/TNFi > immunocompetent. Abstr#0457 #ACR21 @RheumNow https://t.co/lf8cAEWGXf
Abst0437 #ACR21 @RheumNow factors assoctd w/poor response to mRNA Covid-19 vaccine in rheum pts Rx w/Rituxan: ⬆️ exposure to RTX over time, ⬇️ IgG levels prior to RTX, short interval btw RTX course & BNT162b2 vacc. RA highest&ANCA-vasculitis lowest probability for a + response. https://t.co/DsrJBlNvr7
Eric Dein
Tweet
#ACR21 Abst#0457: #COVID19 Vaccine Responses In Patients w Autoimmune Diseas
⭐️Prosp observ: pre-vax▶️5 mo.
⭐️ 90% +Ab responses, but ⬇️ titer
⭐️MMF 21x⬇️ titer, MTX 4.4x⬇️, AZA 3.5⬇️
⭐️BCDT: 58, JAK: 2.6, TNF 2.3
⭐️GC ⬇️ even on <5mg!
https://t.co/BGU4CP9M0s @Rheumnow #ACRbest https://t.co/7QhsTGTwnZ
#ACR21 Plenary Abs#0457 @alhkim #COVaRiPAD study:
👉Patients with inflammatory diseases on #immunosuppression have impaired #SARSCoV2 immunity post-vaccine
👉#Steroids, MMF & B cell depletion therapy more severely affect responses
👉https://t.co/7qTABcpm0h
@RheumNow #ACRBest https://t.co/EfuHjh3vw5
David Liew
Tweet
COVID-19 mRNA vaccination immunogenicity
(vs immunocompetent):
TNFi: 2.3x reduction
JAKi: 2.6x
AZA: 3.5x
MTX: 4.4x
steroids: 9x (but confounded by other meds)
MMF/MPA: 21x
B cell depleting: 57.7x (but 6m gap probably helps)
amazing work led by @alhkim
#ACR21 ABST0457 @RheumNow https://t.co/cl5vBpNzvQ
Dr. @AlHKim on COVaRiPAD data:
274 pts chronic inflam dz (RA/SLE/IBD/SpA/MS/SS,/Vasculitis) vs 53 control
👉90% Ab+ response (⬇️3.4X titer)
👉MMF⬇️21X
👉MTX⬇️4.4X
👉AZA ⬇️3.5X
👉BCDT⬇️ 57.7X
👉JAKi ⬇️2.6 X
👉GCs⬇️9X
👉TNFi impaired neutralization delta
#ACR21 #plenary @rheumnow https://t.co/b0DgLjDi6E
COVaRiPad study - Immunosuppression affects COVID-19 vax Ab levels. 247 pts, 90% seroconverted but @ reduced (3.4 fold) titers. Lowest w/ MMF (21x) and B cell Rx vs MTX/AZA (3-4x). Pts on B cell therapy should wait 6 mos to recv vax #ACR21 Abstr# 0457 https://t.co/1gkCsJSDBk
Richard Conway
Tweet
Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLancetRheum . @rheum_covid project with co-leads @SattuiSEMD and @EBRheum . https://t.co/8NTAafdYRA
Pedro Castillo
Tweet
#ACR2021
Remember, one reason belimumab is so safe is that it does not completely deplete B cells. Particularly important in times of COVID19.
Dr. Petri #GreatDebate @RheumNow
Richard Conway
Tweet
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
David Liew
Tweet
How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVID-19 vaccination?
Better chance of response if:
- RA or SLE, not AAV or IIM
- high serum IgG pre-last RTX
- longer time since last RTX
Israeli data #ACR21 ABST0437 @RheumNow https://t.co/yyuFd0eDH6
Richard Conway
Tweet
Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc
David Liew
Tweet
COVID-19 has been tough on everyone, but especially tough on our patients in rheumatology.
We need to think about the long-term impacts, but also about how we can do it better next time.
@HSpecialSurgery #ACR21 ABST0266 @RheumNow https://t.co/JdOqZ8Svin https://t.co/c0rlY9PfDv
Eric Dein
Tweet
Michael Brenner, Basic Science Year in review: Auto-antibodies against interferon, present prior to COVID-19, mostly in men and increases with age: increases risk to #COVID19 mortality #ACR21 @RheumNow https://t.co/5sFqcBtStD
Janet Pope
Tweet
OK this one is cool. RNA technology used as pro inflammatory in #COVID #vaccinations but paper of RNA vector giving immunetolerance in mouse model of encephalitis. #ACRBest Yr in Review by M Brenner discussion of paper. Double edged sword ⚔️ @RheumNow #ACR21 https://t.co/8sRl351D27
Cassandra Calabrese
Tweet
Join us tomorrow at #ACR21 in the #COVID19 hub at 12p EST where I’ll be discussing outpatient management of high risk covid patients with @LCalabreseDO #mAbs @philipcrobinson @ACRheum https://t.co/LkSw48cnWw
